- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis in America Medical Cannabis Access for Pain Treatment
- News News
- Join Join
Pages tagged "FDA/HHS"
Posted on Blogs by · July 09, 2012 8:00 AMThe article "Medical Marijuana: Clearing Away the Smoke" by Grant, Atkinson, Gouaux, and Wilsey published this month in Bentham Science's 5-year-old, peer-reviewed, National Library of Medicine-indexed and internationally edited Open Neurology Journal represents a major milestone in the consolidation of knowledge and regularizing of clinical practice with regards to the medicinal use of cannabis.
The authors, well-established faculty members or associates at leading American academic medical centers, have yet again reviewed the gold-standard clinical trials-based evidence for medical uses of cannabis and related cannabinoids and have found:
- that it is inaccurate to say that cannabis lacks medical utility or that information on its safety is lacking
- that judgments on relative benefits and risks of cannabis and cannabinoids as medicines need to be viewed within the broader context of risk-benefit of other standard agents as well, many of which are associated with more serious adverse events, and
- that enough information and clinical experience exists that an algorithm can be constructed to guide decision-making for physicians who may be considering recommending medicinal cannabis to patients with neuropathic pain, which the authors offer.
The authors conclude that "it will be useful if marijuana and its constituents can be prescribed, dispensed, and regulated in a manner similar to other medications that have psychotropic effects and some abuse potential" and state that marijuana's Schedule I classification is scientifically untenable and the greatest barrier to forward movement in this area of medicine and medical science. This conclusion is made all the more noteworthy given that the article's first, second, and fourth authors disclose at the end of the manuscript that they have served as consultants and received financial support from major pharmaceutical companies.
Americans for Safe Access is part of a lawsuit challenging the DEA’s scheduling of marijuana as without any currently accepted medical use in treatment in the United States. Download our lawsuit at http://AmericansForSafeAccess.org/downloads/CRC_Appeal.pdf
Sunil Aggarwal, M.D., Ph.D., PGY-3, is a Housestaff Physician at NYU Medical Center and conducts research on the medical geography of cannabis.